Molecular Cancer Therapeutics Online First Articles,

Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab

Epidermal growth factor receptor (EGFR)-mutated lung cancer is a significant subgroup of non-small cell lung cancer. To inhibit EGFR-mediated signals, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed; however, approximately one-third of patients with EGFR-mutated lung cancer do not respond to EGFR-TKIs. More effective inhibition of EGFR-mediated signals is therefore necessary. For cancers expressing mutated EGFR, including EGFR T790M, which confers resistance to first- (gefitinib...

Molecular Cancer Therapeutics Online First Articles

Fri Jun 28, 2019 16:03